1. South Korea Stocks

  2. •

    Energy minerals

  3. •

    Coal
HLB GLOBAL Co., Ltd.

HLB GLOBAL Co., Ltd.

KKRX:003580
1,933.00
KRW
+17.00
(+0.89%)
-10.08EPS
83.33BMarket Cap
HLB GLOBAL Co., Ltd.
KRX:003580
(Korea Stock Exchange)

Recent

price

1,933.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
1,861.27
2,480.19
2,294.14
2,075.7
2,424.76
8,126.04
1,558.48
848.62
639.97
1,225.21
1,147.8
1,443.91
1,056.28
1,883.87
2,000.06
1,995.15
2,121.9
Revenue per Share
-971.5
-1,024.63
-428
-778.5
-69.83
115
-196.35
-40
-546
-935
-934
-340
-273
-538
-173
-150
-30.28
Basic EPS, GAAP
-358.64
82.32
-197.94
-159.25
358.25
552.79
-180.81
-191.77
-94.94
-288.98
-714.43
-243.27
-238.68
-325.98
-99.7
-195.46
-145.21
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2,920.81
3,729.02
3,337.53
2,550.87
2,744.61
3,979.65
3,467.24
3,277.46
3,056.3
2,661.74
2,013.3
2,558.63
1,506.73
1,166.21
1,887.78
1,457.15
1,382.09
Book Value per Share
1,969.71
3,418.99
3,036.01
2,497.36
2,694.94
3,938.09
3,436.57
3,257.02
2,343.03
2,301.4
1,442.77
2,161.31
1,152.36
614.92
1,422.27
1,011.47
927.48
Tangible Book Value per Share
9
9
9
9
9
2
12
18
21
25
31
31
42
42
46
50
50
Basic Weighted Avg Shares
17,550
23,387
21,626
19,572
22,864
15,301
18,256
15,686
13,238
30,028
35,377
45,046
44,592
79,866
92,943
100,286
107,078
Sales/Revenue/Turnover
-22.57
-9.57
-17.45
-16.18
-0.82
8.17
11.29
-2.98
-34.89
18.99
-40.01
-29.62
-33.06
-16.16
-2.43
-9.86
-7.43
Operating Margin (%)
6,734
4,272
4,283
5,156
4,212
585
446
479
926
2,727
5,036
6,325
5,747
5,816
6,079
3,872
3,371
Depreciation Expense
-9,160
-9,662
-4,035
-7,340
-659
217
-2,300
-739
-11,294
-22,915
-28,787
-10,607
-11,525
-22,808
-8,039
-7,540
-1,528
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-52.2
-41.31
-18.66
-37.51
-2.88
1.42
-12.6
-4.71
-85.32
-76.31
-81.37
-23.55
-25.85
-28.56
-8.65
-7.52
-1.43
Profit Margin (%)
-10,450
7,460
8,139
7,885
9,236
11,120
15,683
26,077
25,557
26,648
9,355
14,512
-1,182
-10,235
11,685
8,275
6,527
Working Capital
5,817
3,983
5,859
6,316
5,322
- -
- -
- -
13,524
8,623
17,031
3,674
1,626
8,339
865
1,178
639
LT Debt
32,940
40,958
36,659
27,411
26,119
37,526
44,316
62,846
72,355
81,067
73,620
113,359
68,009
51,948
95,065
75,505
71,138
Total Equity
- -
- -
- -
- -
- -
2.65
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
1.72
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-28.66
-30.82
-12.11
-26.44
-2.64
0.68
-5.62
-1.38
-17.16
-31.73
-40.69
-12.23
-13.44
-40.28
-11.36
-9.09
-2.09
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
27,839
25,441
24,967
LT Borrowings
- -
- -
- -
LT Finance Leases
1,178
853
639
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
51
51
Market Capitalization
117,526
100,707
83,332

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
46,038
45,388
44,080
Cash, Cash Equivalents & STI
16,856
14,526
9,993
Accounts Receivable, Net
5,356
7,295
9,065
Inventories
20,298
19,664
22,766
Total Current Liabilities
37,763
37,338
37,553
Payables & Accruals
- -
- -
- -
ST Debt
27,839
25,441
24,967
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.06%
10.55%
-20.58%
Free Cash Flow
24.08%
9.99%
112.06%
Net Income, GAAP
29.84%
-5.51%
-6.22%
Sales/Revenue/Turnover
26.39%
25.94%
7.9%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
29,265
25,720
20,265
20,665
92,943
2025
23,998
27,044
27,434
21,809
100,286
2026
26,671
31,164
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7.18
2
-72
-102.55
-173
2025
-96
-80
-14
39
-150
2026
-28.36
-27
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Coal India Ltd. (NSE:COALINDIA)
PT Dian Swastatika Sentosa Tbk (IDX:DSSA)
PT Alamtri Resources Indonesia Tbk (IDX:ADRO)
PT Darma Henwa Tbk (IDX:DEWA)
PT Bukit Asam (Persero) Tbk (IDX:PTBA)
Alpha Metallurgical Resources, Inc. (NYSE:AMR)
Business
HLB GLOBAL Co., Ltd., previously operating as NEXT SCIENCE Co., Ltd. until its name change in April 2022, and with roots tracing back to its establishment in 1962, engages in a diverse array of business operations. The company plays a significant role in the resource sector, specializing in the methodical collection of premium sea sand and various aggregates, including gravel and fine aggregates, which are then supplied to concrete production facilities through a process that emphasizes stringent cleaning and salt management. Beyond marine resources, HLB GLOBAL extends its reach into media commerce, distributing a wide range of consumer products, from automotive accessories and fragrances to household items, leveraging its digital platforms and content for direct customer engagement. The company also maintains a strong presence in the consumer market with its cosmetics division, which manufactures and sells beauty products and functional health foods, notably through its Elishacoy brand, which offers skincare, sun protection, and hair care items to international markets including the United States, Europe, China, and Japan. Furthermore, HLB GLOBAL is active in the food and beverage retail sector, producing and distributing items such as fermented milk, various teas, confectionery, and jams, prominently featuring its "I'm Alive Kombucha" products, distributed globally. Demonstrating a commitment to environmental innovation, the firm has ventured into smart farm technology since 2021, focusing on ICT-driven solutions like green walls to enhance urban environments and air quality. Strategically, HLB GLOBAL maintains a presence in the biopharmaceutical field, undertaking investments and exploring opportunities in this segment, aligning with the broader HLB Group's significant advancements in developing novel treatments, particularly in oncology, and in-vitro diagnostics. The company is headquartered in Sabuk-eup, South Korea.